Syndax Pharmaceuticals, Inc. Common Stock (SNDX) Stock
NASDAQ · SNDX
17.62
Fundamentals
Market cap
$1.57B
Price / Earnings ratio
-7.2x
Price / Sales ratio
6.3x
Price / Book ratio
104.6x
Return on assets
-0.5%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Syndax Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees298
CEOMr. Michael A. Metzger M.B.A.
IPO DateMar 3, 2016
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael A. Metzger M.B.A. | CEO & Director | 1971 |
| Mr. Keith Alan Goldan CPA | CFO, Treasurer & Principal Accounting Officer | 1971 |
| Mr. Luke J. Albrecht J.D. | Senior VP, General Counsel & Secretary | 1979 |
| Mr. Steven Closter | Chief Commercial Officer | 1969 |
| Dr. Nicholas A.J. Botwood B.Sc., MBBS | Head of Research & Development and Chief Medical Officer | 1968 |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder | 1957 |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | 1950 |
| Dr. Michael Downes Ph.D. | Co-Founder | — |
| Sharon Klahre | Vice President of Investor Relations & Communications | — |
Fundamentals
Valuation
Market cap$1.57B
Price-to-sales ratio6.26
Price-to-book value104.56
Price-earnings ratio-7.20
Return on Equity-257.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-2.51
Income Statement
Average volume1,389,546
EBITDA$-204.80M
1 year high (52w)$25.59
1 year low (52w)$12.99
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



